Porton Down, UK; 11 April 2011: GW Pharmaceuticals plc (AIM:GWP) today announces that it has entered into an exclusive licence agreement for Novartis Pharma AG to commercialise Sativex® in Australia and New Zealand, Asia (excluding Japan, China and Hong Kong), Middle East (excluding Israel/Palestine) and Africa.
Sativex® has been developed as a treatment for spasticity due to Multiple Sclerosis (MS). It is anticipated that regulatory filings for Sativex® in MS will begin in some of the countries in the above region during 2011. Sativex® is also in Phase III clinical development for the treatment of cancer pain.
